Erratum {#Sec1}
=======

After publication of this work \[[@CR1]\], we noted that we inadvertently failed to include the complete list of all coauthors and that sample sizes of some of the trials listed in Table two were incorrect.

The full list of authors has now been added and includes the names of all authors within the i-WIP Collaborative Network. The Authors' contributions and competing interests section modified accordingly. We are publishing this erratum to update the author list, which is as follows:

Anneloes E Ruifrok, Ewelina Rogozinska, Mireille NM van Poppel, Girish Rayanagoudar, Sally Kerry, Christianne JM de Groot, SeonAe Yeo, Emma Molyneaux, Fionnuala McAuliffe, Lucilla Poston, Tracy Roberts, Richard D Riley, Arri Coomarasamy, Khalid Khan, Ben Willem Mol, Ruben Barakat Carballo, Maria Perales, Annick Bogaerts, Jose G Cecatti, Fernanda Surita, Jodie Dodd, Julie Owens, Nermeen El Beltagy, Roland Devlieger, Helena Teede, Cheryce Harrison, Lene Haakstad, Garry X Shen, Alexis Shub, Narges Motahari, Janette Khoury, Serena Tonstad, Riitta Luoto, Tarja I Kinnunen, Kym Guelfi, Fabio Facchinetti, Elisabetta Petrella, Suzanne Phelan, Tânia T Scudeller, Kathrin Rauh, Hans Hauner, Kristina Renault, Linda Reme Sagedal, Ingvild Vistad, Signe Nilssen Stafne, Siv Mørkved, Kjell Åsmund Salvesen, Christina Vinter, Marcia Vitolo, Arne Astrup, Nina Rica Wium Geiker and Shakila Thangaratinam.

The sample sizes of trials included in Table two have been corrected (Table [1](#Tab1){ref-type="table"}). We are publishing this erratum to update these trial sample sizes, which include Dodd 2014 (*n* = 2212), Prevedel 2003 (*n* = 41), Renault 2013 (*n* = 425), Stafne 2012 (*n* = 855), Vinter 2011 (*n* = 360), Walsh 2012 (*n* = 800) and Wolff 2008 (*n* = 66).Table 1Studies with provisional support and consideration to share individual patient dataStudy YearCountryStudy CharacteristicsOutcomesSample sizeMaternalFetalAlthuizen 2012NetherlandsEthnically diverse , no BMI restrictions, age n.r., GA at inclusion \< 14 wks, glucose status n.r., other risk factors: n.r.GWG, GDM, preterm delivery, CSbirth weight, macrosomia269Barakat 2009SpainCaucasian, BMI restrictions n.r., age 25--35 yrs, GA at inclusion n.r. (total at least 26 wks intervention), glucose status n.r., no known pre-existing health problemsGWG, GA, preterm deliverybirth weight, LGA, SGA, AS, macrosomia (\>4000g)142Barakat 2011SpainSpanish (white), BMI restrictions n.r., age 23--38 yrs, GA at inclusion 1st prenatal visit, glucose status n.r., no known pre-existing health problemsGWG, GA CS, vaginal deliverybirth weight, AS80Barakat 2013SpainCaucasian, no BMI restrictions, age n.r., GA at inclusion \<10 wks, glucose status n.r., no known pre-existing health problemsGWG, GA, GDM, PIH, preterm deliverybirth weight, AS765Bogaerts 2012BelgiumEthnically diverse , BMI ≥ 29 kg/m2, age n.r., GA at inclusion \< 15 wks, nondiabetic, other risk factors: n.rGWG, GA, PE, PIH, GDM, IOL, CS, vaginal deliverybirth weight, AS197Cavalcante 2009BrazilRace n.r., no morbid obesity, age restrictions n.r., GA at inclusion 16--20 wks, glucose status n.r., no known pre-existing health problemsGWG, preterm deliverybirth weight71Clapp 1997USARace n.r., no morbid obesity, age restrictions n.r., GA at inclusion 8 wks, glucose status n.r., no known pre-existing health problemsGWGbirth weight51Clapp 2000USARace n.r., no morbid obesity, age restrictions n.r., GA at inclusion 8 wks, glucose status n.r., no known pre-existing health problemsGWG, GAbirth weight12Dodd 2014AustraliaRace n.r., BMI ≥ 25 kg/m^2^, age restrictions n.r., GA at inclusion \<20 wks, nondiabetic, other risk factors: n.r.PE, PIH, GDM, IOL, CS, Preterm deliveryLGA, macrosomia (\>4000g), hypoglycaemia, shoulder dystocia, admission to NICU2,212El Beltagy 2013EgyptRace n.r., BMI: obese, age restrictions n.r., GA at inclusion: first antenatal visit, glucose status n.r., other risk factors: n.r.GWG, GDMbirth weight, macrosomia100Grant 2013CanadaRace : predominantly non-Caucasian, BMI restrictions n.r., age \>18 yrs, GA at inclusion n.r., glucose status: impaired glucose tolerance or GDM, no known pre-existing health problemsGWGbirth weight, macrosomia47Guelinckx 2010BelgiumCaucasian, BMI ≥ 29 kg/m^2^, age restrictions n.r., GA at inclusion \<15 wks, nondiabetic, no known pre-existing health problemsGWG, GA, PE, PIH, IOL, CSbirth weight, LGA85Haakstad 2011NorwayRace n.r., BMI restrictions n.r., age restrictions n.r., GA at inclusion \<24 wks, glucose status n.r., no known pre-existing health problemsGWG105Hui 2006CanadaEthnically diverse, BMI restrictions n.r., age restrictions n.r., GA at inclusion \<26 wks, nondiabetic, no known pre-existing health problemsGWG, GA, GDMbirth weight, LGA45Hui 2011CanadaRace n.r., BMI restrictions n.r., age restrictions n.r., GA at inclusion 20--26 wks, nondiabetic, no known pre-existing health problemsGWG, GA, GDM, CSbirth weight, LGA224Jackson 2010USAEthnically diverse, BMI restrictions n.r., age \>18 yrs, GA at inclusion \<26 wks, glucose status n.r., other risk factors: n.r.GWG321Jeffries 2009AustraliaRace n.r., BMI restrictions none, age \>18 - \<45 yrs, GA at inclusion \<14 wks, nondiabetic, other risk factors: n.r.GWG, PE, PIH, GDM , preterm delivery, CSbirth weight, LGA, SGA, hypoglycaemia, shoulder dystocia236Khaledan 2010IranRace n.r., BMI restrictions n.r., age restrictions n.r., GA at inclusion 24--32 wks, no Diabetes Mellitus type 1 (DM1) with poor control, no known pre-existing health problemsGWG, GA, CSbirth weight39Khoury 2005NorwayCaucasian, BMI 19--32 kg/m^2^. age 21--38 yrs, GA at inclusion 17--20 wks, nondiabetic, no known pre-existing health problemsGWG, PE, preterm deliverybirth weight, SGA, intra-uterine death290Luoto 2011FinlandRace n.r., BMI \>17 kg/m^2^, age \>18 yrs, GA at inclusion 8--12 wks, nondiabetic, no known pre-existing health problemsGWG, GA, PE, GDMbirth weight, LGA, SGA399Nascimento 2011BrazilRace n.r., BMI \>26 kg/m^2^, age \>18 yrs, GA at inclusion 14--24 wks, nondiabetic, no known pre-existing health problemsGWG, PIH, GDM, CSbirth weight, AS, LGA, SGA82Ong 2009AustraliaRace n.r., obese, age restrictions n.r., GA at inclusion 18 wks, nondiabetic, other risk factors: n.r.GWG12Oostdam 2012NetherlandsEthnically diverse, BMI ≥ 25.0 kg/m^2^, age \> 18 yrs, GA at inclusion \<20 wks, nondiabetic, no known pre-existing health problemsGWG, GDMbirth weight124Petrella 2013ItalyEthnically diverse , BMI ≥ 25.0 kg/m^2^, age \> 18 yrs, GA at inclusion 12 wks, nondiabetic, no known pre-existing health problemsGWG, GDM, PIH, preterm delivery63Phelan 2011USAEthnically diverse, BMI ≥19.8-26.0 kg/m^2^, age \>18 yrs, GA at inclusion 10--16 wks, glucose status n.r., no known pre-existing health problemsGWG, GA, PE, PIH, GDM, preterm delivery, CSbirth weight, macrosomia, birth weight \<2500g401Poston 2013United KingdomRace: n.r., BMI ≥30 kg/m^2^, age restrictions n.r., GA at inclusion \>15^+0^ weeks and \<17^+6^, , nondiabetic, no known pre-existing health problemsGA, GWG, PE, GDM, mode of deliveryBirth weight, macrosomia, still birth183Prevedel 2003BrazilRace: n.r., BMI restrictions n.r., age restrictions n.r. (primiparous or adolescents), GA at inclusion 16--20 wks, glucose status n.a., no known pre-existing health problemsGWG, preterm deliverybirth weight, SGA41Rauh 2013GermanyRace: n.r., BMI ≥18.5 kg/m^2^, age ≥18 yrs, GA at inclusion \<18 wks, nondiabetic, no known pre-existing health problemsGWG, GDM, IOL, CS, preterm deliveryBirth weight LGA, SGA250Renault 2013DenmarkRace: predominantly Caucasian, BMI ≥30 kg/m^2^, age \>18 yrs, GA at inclusion \<16 wks, nondiabetic, no known pre-existing health problemsGWG, GDM, PIH,PE,IOL, CS, preterm deliveryBirth weight, SGA, LGA, Birth weight \>4000g425Sagedal 2014NorwayRace: n.r., BMI ≥19 kg/m^2^, age ≥18 yrs, GA at inclusion \<20 wks, nondiabetic, no known pre-existing health problemsGWG, GDM, CSLGA606Stafne 2012NorwayWhite, no BMI restrictions, age \>18 yrs, GA at inclusion 18--22 wks, nondiabetic, no known pre-existing health problemsGA, PE, PIH, GDM, CSbirth weight, AS, LGA, admission to NICU855Vesco 2013USARace: n.r., BMI ≥30 kg/m^2^, age n.r., GA at inclusion \<20 wks, nondiabetic, no known pre-existing health problemsGWG, GA, PE, PIH, GDM, CS, preterm deliverybirth weight, LGA, SGA, macrosomia (4000g)114Vinter 2011DenmarkCaucasian, BMI 30--45 kg/m^2^, age 18--40 yrs, GA at inclusion 10--14 wks, nondiabetic, no known pre-existing health problemsGWG, PE, PIH, GDM, CSLGA, admission to NICU360Vitolo 2011BrasilRace: n.r., BMI restrictions: none, age \<35yrs, GA at inclusion 10--29 wks, nondiagetic, no known pre-existing health problemsGWG,PE, PIH, GDM, preterm birthbirth weight315Walsh 2012IrelandRace: n.r., BMI restrictions n.r., age \>18 yrs, GA at inclusion \< 18 wks, nondiabetic, no known pre-existing health problemsGWG, GA, preterm delivery, IOL, CSbirth weight, macrosomia800Wolff 2008DenmarkCaucasian, BMI ≥30 kg/m^2^, age \>18 - \<45 yrs, GA at inclusion \<18 wks, nondiabetic, no known pre-existing health problemsGWG PE, PIH, GDM , CSbirth weight66Yeo 2012USAEthnically diverse, BMI \>19.8 kg/m^2^, no age restrictions, GA at inclusion 18 wks, nondiabetic, no known pre-existing health problemsGWG, PE, PIHbirth weight17*AS* Apgar score, *CS* Caesarean section, *GA* Gestational Age, *GDM* Gestational diabetes mellitus, *GWG* Gestational weight gain, *IOL* Induction of labour, *LGA* Large for gestational age, *NICU* Neonatal Intensive Care Unit, *n.r.* not reported, *PE* Pre eclampsia, *PIH* Pregnancy Induced hypertension, *RDS* Respiratory Distress Syndrome, *SGA* Small for gestational age

The online version of the original article can be found under doi:10.1186/s2046-4053-3-131-y.
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